Genetics Testing Availability during COVID-19 outbreak

UW Genetics Testing Status During the COVID-19 Outbreak

This page details the current status of genetic and molecular testing performed by the UW Genetics and Solid Tumors Laboratory (GSTL). To the greatest extent possible, the GSTL aims to continue to serve our patients and providers throughout the COVID-19 (Coronavirus) pandemic. However, service delays and/or disruptions may occur.

Note that high priority testing, or testing that has been suspended in-house, may be sent out to the UW's preferred reference laboratories.

For additional questions or concerns, please contact the clinical genomics analysis team at 206-598-1149.

UW Genetics laboratory's current service status is Level 1 (last updated: 1/19/2021)

Level 1 (Currently in effect):

• CellFree DNA Prenatal Screen [PDNAS]: No change in service level (2x weekly)
• UW OncoPlex Cancer Gene Panel [OPX] OncoPlex testing: No change in service level (weekly)
• BROCA Cancer Risk Panel [BROCA]/ColoSeq - Lynch and Polyposis Panel [COSEQ]: Will be run biweekly. Expect results to be delayed but delivered within 6 weeks.
• Other germline testing (Alpha Thalassemia DNA Screen [ATHAL], Alpha Hemoglobin DNA Sequence [HASEQ], Beta Hemoglobin DNA Sequencing [HBSEQ], Fragile X Mental Retardation [FX], Huntington Disease DNA Screen [HDTEST], Spinocerebellar Ataxia Panel [SCAPN], Cystic Fibrosis DNA Screen [CFDNA], Prothrombin DNA Screen [PRODS], Factor V DNA Screen [F5DNA], Hemochromatosis DNA Screen [HEMDNA]): Will be run biweekly. We expect turn-around-time to be increased for these tests.

Level 2 (NOT in effect):

• PDNAS: No change in service level (2x weekly).
• OncoPlex: High priority testing will be limited to lung and melanoma cases. Other case types (prostate, breast, etc.) will be triaged for other testing as appropriate (including assessment for MSI by IHC).
• OncoPlex Single Gene: Will be run with laboratory director approval or sent out to a preferred reference lab.
• BROCA/ColoSeq and all other germline testing will remain in house and run with reduced frequency.

Level 3 (NOT in effect):

• PDNAS: No change in service level (2x weekly).
• OncoPlex: No change from level 2 operations.
• BROCA: No change from level 2 operations (biweekly).
• All other testing postponed or sent out as needed.

Level 4 (NOT in effect):

• PDNAS: No change in service level (2x weekly).
• All other testing postponed or sent out as needed.

Level 5 (NOT in effect):

• Complete service disruption; testing may be run on case-by-case basis.